SLC27A1 overexpression correlates with lactylation and poor colorectal cancer progression Authors: Yu Qi, Shumin Deng, Jun Zhang, Kuansong Wang Published: 2026 ABSTRACT AbstractSLC27A1 (solute carrier family 27 member 1), which encodes fatty acid transport protein 1 (FATP1), has been implicated in the development and progression of various cancers. However, its role in colorectal cancer (CRC) remains to be fully elucidated. This study combined a series of bioinformatics analyses and biological experiments to characterize the comprehensive function of SLC27A1 in CRC. The expression of SLC27A1 in CRC was analyzed using multiple databases. Bioinformatics methods were employed to explore the associations between SLC27A1 expression levels in CRC and its clinical significance, as well as immune infiltration. The function and potential mechanism of SLC27A1 in CRC were investigated through Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, gene set enrichment analysis (GSEA), and in vitro experiments. SLC27A1 was significantly upregulated in CRC. Its high expression correlated with adverse clinicopathological features and poor prognosis in CRC patients. SLC27A1 expression was closely linked to immune cell infiltration in CRC. GSEA analysis revealed that SLC27A1 is involved in multiple tumor-associated signaling pathways and negatively correlates with the tricarboxylic acid cycle and pyruvate metabolism. In vitro experiments demonstrated that SLC27A1 knockdown inhibited CRC cell proliferation and migration. In contrast, SLC27A1 overexpression promoted glucose uptake and lactate accumulation in CRC cells. Further analysis showed that SLC27A1 was significantly associated with multiple lactylation-related genes. The results of this study demonstrate that high expression of SLC27A1 is closely associated with poor prognosis, protein lactylation, and immune cell infiltration in CRC. Knockdown of SLC27A1 can suppress the proliferation and migration abilities of CRC cells. Therefore, SLC27A1 may serve as a promising independent prognostic biomarker and a potential therapeutic target.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52152-z.Keywords: SLC27A1, FATP1, Colorectal cancer, Survival prognosis, Lactylation, Immune infiltrationSubject terms: Biomarkers, Cancer, Computational biology and bioinformatics, Oncology Introduction Colorectal cancer (CRC) is one of the most prevalent and life-threatening malignancies worldwide, imposing a substantial burden on global public health and clinical practice. The incidence and mortality of CRC vary widely across regions, genders, and lifestyles1–5. Major risk factors include a high-fat and low-fiber diet, physical inactivity, smoking, and alcohol consumption6,7. Thus, early screening is critical for reducing CRC incidence and mortality7–9. Identifying effective diagnostic biomarkers will help improve early detection and reduce the disease burden of CRC10,11. SLC27A1 (solute carrier family 27 member 1) encodes fatty acid transport protein 1 (FATP1), which primarily mediates transmembrane transport of long-chain fatty acids and regulates lipid metabolism12,13. As a long-chain fatty acid transporter, FATP1 facilitates the uptake of extracellular fatty acids into cells and participates in their activation14,15. In adipocytes, it modulates fat accumulation and plays a key role in lipid processing16. Additionally, it is involved in glycerophospholipid biosynthesis and the transport of lipids across the blood–brain barrier17. Studies have demonstrated that SLC27A1 enhances macrophage-mediated inflammatory responses through interactions with ceramide and the c-Jun N-terminal kinase signaling pathway18–20. SLC27A1 is widely expressed in many tissues, including adipose tissue, ovary, brain, liver, and muscle21–24. In breast cancer, SLC27A1 is regulated by estrogen receptor β (ER-β) and may serve as a novel therapeutic target25,26. Besides, high SLC27A1 expression has been linked to the progression of invasive pituitary adenomas, suggesting its potential as a prognostic indicator for tumor progression27. Due to its roles in lipid metabolism and inflammatory response, SLC27A1 has become a focus of research in metabolic and inflammation-related diseases28–30. Future studies will further clarify its mechanisms and support the development of FATP1-targeted therapies. Overall, SLC27A1 and its encoded FATP1 are essential for fatty acid transport, lipid homeostasis, and inflammatory responses, with potential regulatory roles in various diseases31–33. While direct research on SLC27A1 in CRC remains limited, its encoded FATP1 protein plays a key part in fatty acid transport and metabolism. Notably, aberrant fatty acid metabolism is closely linked to CRC initiation and progression34. Studies have shown that altered fatty acid metabolism is one of the vital characteristics of CRC. For instance, fatty acid-binding protein 1 (FABP1) is downregulated in microsatellite instability (MSI) CRC, which is associated with changes in the immune microenvironment35. Besides, lipid metabolic reprogramming enables tumor cells to adapt to metabolic stress and drive CRC cell growth. SLC25A1 (a mitochondrial citrate carrier), for example, is upregulated in CRC. It promotes tumor growth and survival by enhancing de novo lipid synthesis and oxidative phosphorylation (OXPHOS)34. Recent studies also indicate that SLC27A1 promotes CRC metastasis by facilitating diacylglycerol‑3‑phosphate synthesis via long-chain fatty acid transport36. Given the critical role of SLC27A1 in fatty acid turnover, future studies may further explore its specific functions in CRC and its potential mechanisms in tumor metabolic reprogramming29. In addition to lipid metabolism, the Warburg effect is a core feature of metabolic reprogramming in CRC. It is characterized by increased glucose consumption and high lactate accumulation37. Emerging evidence suggests that this accumulated lactate not only fuels tumor progression but also serves as an essential precursor for protein lactylation, a novel post-translational modification linked to tumor malignancy. Whether SLC27A1 coordinates lipid transport with such glucose-driven lactylation in CRC remains a critical knowledge gap. Therefore, SLC27A1 holds promise as a potential diagnostic biomarker or therapeutic target for CRC, meriting further investigation33,34. In summary, while recent studies have implicated SLC27A1 in CRC metastasis via fatty acid transport, its comprehensive clinical significance and detailed molecular mechanisms remain to be fully elucidated. In recent years, the widespread use of public databases and bioinformatics tools has enabled systematic analysis of cancer-related traits. Therefore, to gain a deeper insight into SLC27A1’s role in CRC, this study systematically investigated the associations between SLC27A1 expression, clinicopathological features, and prognosis, followed by experimental exploration of its potential biological functions. In addition, in vitro assays were conducted to explore the effects of SLC27A1 on CRC cell proliferation and metastasis, aiming to elucidate its function and underlying mechanisms in CRC and address the existing research gaps in this area. Results SLC27A1 is highly expressed in CRC We analyzed pan-cancer expression differences of SLC27A1 using data from the TCGA database. As shown in Fig. 1, SLC27A1 expression varies significantly across tumor types (Fig. 1A), with marked upregulation in cholangiocarcinoma, colon adenocarcinoma, renal chromophobe carcinoma, clear cell renal cell carcinoma, hepatocellular carcinoma, rectal adenocarcinoma, and gastric cancer. Given its role in digestive metabolism, we further explored SLC27A1 expression in CRC. Analyses of the TCGA-COADREAD dataset showed that SLC27A1 mRNA was significantly upregulated in CRC tumor tissues compared to normal tissues (Fig. 1B, C). Expression levels of SLC27A1 in CRC. (A) Pan‑cancer expression profile of SLC27A1 across TCGA tumor types. (B) SLC27A1 expression in unpaired CRC samples (647 tumor, 51 normal) from the TCGA dataset. (C) SLC27A1 expression in 51 paired samples from the TCGA dataset. (D) Representative images of IHC staining for SLC27A1 in normal colonic epithelial tissues and CRC tissues. Scale bar: 100 μm (left) and 20 μm (right). (E) Statistical analysis of SLC27A1 IHC scores. (F) SLC27A1 mRNA and protein levels in normal colonic epithelial cells and CRC cell lines (Original blots are presented in Supplementary Information file). *P < 0.05, **P < 0.01, ***P < 0.001. Furthermore, IHC staining of patient tissues confirmed high SLC27A1 expression in CRC tumors, with localization to the cytoplasm and cell membrane (Fig. 1D, E). Subsequently, qRT-PCR and Western Blot were performed to detect SLC27A1 expression at both mRNA and protein levels in the normal colonic epithelial cell line FHC and CRC cell lines. As shown in Fig. 1F, SLC27A1 expression was generally higher in CRC cell lines than in the normal cell line. Notably, among the CRC cell lines, HCT8 and SW480 exhibited the highest relative expression levels, whereas LoVo and SW620 showed relatively lower expression. Based on this expression profile, these four cell lines (HCT8, SW480, LoVo, and SW620) were selected for subsequent loss-of-function and gain-of-function experiments. Together, these results confirm that SLC27A1 is significantly overexpressed in CRC. SLC27A1 expression correlates with adverse clinicopathological features in CRC patients Logistic regression analysis using the TCGA COADREAD dataset revealed that high SLC27A1 expression was significantly associated with adverse clinicopathological features of CRC (Table 1). These included age, pathological stage, histological grade, residual tumor, and lymph node invasion. Similarly, higher SLC27A1 levels were observed in patients with advanced T/N stages, elevated CEA, and adverse DSS/PFI events (Fig. 2). These data further suggest that SLC27A1 is significantly upregulated in CRC patients and may promote their clinicopathological progression. Table 1SLC27A1 expression correlated with clinicopathological characteristics analyzed by logistic regression of CRC in TCGA.Characteristics, n (%) OR (95% CI)Expression of SLC27A1P valueLow (n = 322)High (n = 322)Gender1.091 (0.801 – 1.487)0.580Male175 (27.2%)168 (26.1%)Female147 (22.8%)154 (23.9%)Age1.392 (1.017 – 1.904)0.038 < = 65151 (23.4%)125 (19.4%) > 65171 (26.6%)197 (30.6%)BMI0.876 (0.552 – 1.391)0.574 < = 2549 (14.9%)58 (17.6%) > 25109 (33.1%)113 (34.3%)Pathologic T stage1.913 (1.289 – 2.837)0.001T1 & T282 (12.8%)49 (7.6%)T3 & T4238 (37.1%)272 (42.4%)Pathologic N stage1.588 (1.158 – 2.178)0.004N0202 (31.6%)166 (25.9%)N1 & N2118 (18.4%)154 (24.1%)Pathologic M stage1.027 (0.653 – 1.615)0.908M0238 (42.2%)237 (42%)M144 (7.8%)45 (8%)Pathologic stage1.376 (1.002 – 1.890)0.049Stage I & Stage II187 (30%)162 (26%)Stage III & Stage IV125 (20.1%)149 (23.9%)Residual tumor0.467 (0.240 – 0.909)0.023R0226 (44.3%)242 (47.5%)R1&R228 (5.5%)14 (2.7%)CEA level1.253 (0.840 – 1.867)0.269 < = 5135 (32.5%)126 (30.4%) > 571 (17.1%)83 (20%)Perineural invasion1.103 (0.612 – 1.987)0.745No83 (35.3%)92 (39.1%)Yes27 (11.5%)33 (14%)Lymphatic invasion1.672 (1.196 – 2.338)0.003No191 (32.8%)159 (27.3%)Yes97 (16.7%)135 (23.2%)OS event0.094Alive266 (41.3%)249 (38.7%)Dead56 (8.7%)73 (11.3%)DSS event0.032No280 (45%)264 (42.4%)Yes30 (4.8%)48 (7.7%)PFI event < 0.001No261 (40.5%)218 (33.9%)Yes61 (9.5%)104 (16.1%)Bold values indicate statistically significant differences with P < 0.05; all non-bold values represent non-significant differences (P ≥ 0.05). SLC27A1 expression correlated with clinicopathological characteristics analyzed by logistic regression of CRC in TCGA. Bold values indicate statistically significant differences with P < 0.05; all non-bold values represent non-significant differences (P ≥ 0.05). SLC27A1 expression correlates with adverse clinicopathological features in CRC patients. SLC27A1 expression in CRC correlates with (A) pathological T stage, (B) pathological N stage, (C) pathological M stage, (D) pathological stage, (E) OS events, (F) PFI events, (G) DSS events, and (H) CEA levels. *P < 0.05, **P < 0.01, ***P < 0.001. High SLC27A1 expression correlates with poor prognosis in CRC patients To determine whether SLC27A1 expression affects patient survival, Kaplan–Meier survival analysis was used to examine its association with CRC patient prognosis. Results showed that high SLC27A1 expression correlated with shorter overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in CRC (Fig. 3A-C). Further subgroup analyses showed that high SLC27A1 expression was significantly correlated with poor OS in multiple subgroups. These included female patients, patients older than 65 years, adenocarcinoma, pathological T4 stage, M0 stage, CEA ≤ 5, R0 resection, complete pathological response, and absence of perineural invasion (Fig. 3D-L). These findings indicate that high SLC27A1 expression predicts to poor prognosis in CRC patients. High SLC27A1 expression associates with poor prognosis in CRC. (A-C) Kaplan–Meier curves showing that CRC patients with high SLC27A1 expression had poorer (A) overall survival, (B) disease-specific survival, and (C) progression-free survival compared to those with low SLC27A1 expression in TCGA datasets. (D-L) Kaplan–Meier curves depicting the prognostic value of SLC27A1 expression for overall survival in different CRC subgroups, including (D) female, (E) age > 65, (F) histological type (G) T4, (H) M0, (I) CEA ≤ 5 (J) R0, (K) CR(Complete Response), and (L) no perineural invasion. High SLC27A1 expression serves as an independent risk factor for survival prognosis in CRC patients To better predict the duration of recurrence-free survival after CRC treatment, we performed Cox regression analysis with PFI as the dependent variable (Table 2). Multivariate Cox proportional hazards regression was used to assess the impact of multiple clinical variables and SLC27A1 expression on PFI in CRC patients (Fig. 4A). Results showed that high SLC27A1 expression was an independent prognostic factor for PFI in CRC patients. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic value of SLC27A1 in CRC. SLC27A1 expression exhibited good diagnostic performance in distinguishing tumor from non-tumor tissues (AUC = 0.747) (Fig. 4B). Additionally, the AUC values for SLC27A1 expression in predicting 1-year, 3-year, and 5-year PFI were 0.618, 0.609, and 0.570, respectively. These values indicate moderate predictive accuracy for short-term survival (Fig. 4C). We then constructed a nomogram integrating SLC27A1 expression with key clinical features. It showed good performance in predicting 1 , 3 , and 5 year survival in CRC patients as well (Fig. 4D-E). These findings support SLC27A1 as a reliable prognostic biomarker in CRC. Table 2Univariate and multivariate Cox regression analyses of clinical characteristics associated with PFI of CRC in TCGA.CharacteristicsTotal(N)Univariate analysisMultivariate analysisHazard ratio (95% CI)P valueHazard ratio (95% CI)P valueSLC27A1643Low322ReferenceReferenceHigh3211.826 (1.331—2.506) < 0.0012.739 (1.653—4.537) < 0.001Gender643Male342ReferenceFemale3010.822 (0.602—1.121)0.216Age643 < = 65276Reference > 653671.006 (0.737—1.371)0.972BMI329 < = 25107Reference > 252221.381 (0.857—2.224)0.185Pathologic T stage640T1&T2131ReferenceReferenceT3&T45093.198 (1.814—5.636) < 0.0012.718 (0.951—7.770)0.062Pathologic N stage639N0367ReferenceReferenceN1&N22722.624 (1.916—3.592) < 0.0010.397 (0.117—1.346)0.138Pathologic M stage563M0474ReferenceReferenceM1895.577 (3.945—7.884) < 0.0013.618 (1.677—7.805)0.001Pathologic stage622Stage I & Stage II348ReferenceReferenceStage III & Stage IV2742.924 (2.115—4.044) < 0.0012.039 (0.517—8.042)0.309Histological type632Adenocarcinoma549ReferenceMucinous adenocarcinoma831.086 (0.687—1.718)0.724Residual tumor509R0467ReferenceReferenceR1&R2424.044 (2.605—6.280) < 0.0011.463 (0.717—2.984)0.296CEA level414 < = 5260ReferenceReference > 51542.628 (1.777—3.886) < 0.0011.864 (1.120—3.103)0.017Bold values indicate statistically significant differences with P < 0.05; all non-bold values represent non-significant differences (P ≥ 0.05). Univariate and multivariate Cox regression analyses of clinical characteristics associated with PFI of CRC in TCGA. Bold values indicate statistically significant differences with P < 0.05; all non-bold values represent non-significant differences (P ≥ 0.05). Diagnostic and prognostic value of SLC27A1 in CRC. (A) Forest plot showing potential prognostic factors for disease-specific survival. (B) ROC curve of SLC27A1 in CRC. (C) Time-dependent survival ROC curve for SLC27A1 in CRC. (D) Nomogram and (E) corresponding calibration curve illustrating the correlation between high SLC27A1 expression and poor prognosis in CRC. Correlation between SLC27A1 expression and immune infiltration Lipid metabolism is known to affect immune cell function. For instance, a study on breast cancer found that fatty acid-binding protein 5 (FABP5) is highly expressed in regulatory T cells (Tregs). FABP5 inhibition disrupts lipid metabolism and mitochondrial function in Tregs, promotes IL-10 production, and enhances the immunosuppressive activity of Tregs; the tumor microenvironment (TME) also influences FABP5 expression and Tregs immune function38. Similarly, fatty acid transport protein 2 (FATP2) is specifically upregulated in polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs, a specialized type of neutrophil). By modulating lipid metabolism and signaling, FATP2 confers immunosuppressive activity on PMN-MDSCs, driving tumor immune evasion—effectively reprogramming neutrophils39. FATP2 endows neutrophils with immunosuppressive capacity to facilitate tumor growth, and targeting FATP2 can trigger anti-tumor immunity and enhance the efficacy of immune checkpoint blockade therapy. These findings highlight close links between fatty acid metabolism-related genes and tumor immunity. Here, whether SLC27A1 (also known as FATP1), another key member of the FATP family, possesses immunoregulatory functions similar to FATP2 remains unclear and requires in-depth exploration. Based on the above evidence, we speculate that SLC27A1 may be potentially associated with tumor immune responses.To investigate how SLC27A1 expression affects tumor immune responses, we used the TCGA database and the single-sample gene set enrichment analysis (ssGSEA) algorithm to assess associations between SLC27A1 levels and immune cell infiltration in CRC patients. Results showed that SLC27A1 expression was positively correlated with infiltration levels of natural killer (NK) cells, immature dendritic cells (iDCs), macrophages, DCs, eosinophils, central memory T (Tcm) cells, effector memory T (Tem) cells, NK CD56 bright cells, and Th1 cells. In contrast, it was negatively correlated with infiltration of helper T (Th) cells and Th2 cells (Fig. 5A). A strong positive correlation was observed with NK cell infiltration (R = 0.431, P < 0.001) (Fig. 5B). Association of SLC27A1 expression with immune infiltration in CRC. (A) Correlation analysis between SLC27A1 expression and the relative abundance of 24 immune cell subsets. (B) Scatter plot showing the positive correlation between SLC27A1 expression and NK cell enrichment. (C) Box plots displaying 24 immune cell infiltration differences between high and low SLC27A1 expression groups. (D) Heatmap illustrating the correlation between SLC27A1 expression and immune cell subgroup proportions in CRC. (E) Heatmap showing the correlation of SLC27A1 expression with StromalScore, ImmuneScore, and ESTIMATEScore. (F) Heatmap depicting the distribution of 24 immune cell types in CRC tumors stratified by SLC27A1 expression level. *P < 0.05, **P < 0.01, ***P < 0.001. Subsequently, compared with the low SLC27A1 group, the high expression group showed significantly increased infiltration of iDCs, CD8 + T cells, NK cells, CD56 bright NK cells, macrophages, and Th1 cells, while Th2 cell infiltration was significantly decreased. These findings prompted deeper investigation into SLC27A1-immune infiltration links (Fig. 5C). Next, using CIBERSORT and ESTIMATE algorithms, we evaluated correlations between SLC27A1 and proportions of tumor-infiltrating immune subsets in the TME, with results visualized as heatmaps (Fig. 5D, E). SLC27A1 was related to multiple immune cell types and positively correlated with StromalScore, ImmuneScore, and ESTIMATEScore. Additionally, differences in immune cell composition between low and high SLC27A1 expression groups were compared (Fig. 5F). We also analyzed the correlation between SLC27A1 expression and multiple classic immune checkpoint molecules in CRC tissues (Supplementary Fig. 1). SLC27A1 was positively correlated with PD-L1, CTLA-4, and TIM-3 in CRC. Although the correlation was moderate due to the limited sample size and individual variation in clinical specimens, the consistent positive association still indicates that SLC27A1 may potentially regulate immune checkpoint expression, thereby promoting tumor immune escape and inhibiting anti-tumor immune responses. Collectively, these results suggest SLC27A1 expression may impact the overall immune microenvironment in CRC, with its levels correlating with comprehensive TME characteristics. High SLC27A1 expression promotes CRC proliferation and migration To investigate the role of SLC27A1 in CRC, we knocked down SLC27A1 in relatively high-expression cell lines (HCT8, SW480) and overexpressed it in relatively low-expression lines (LoVo, SW620). Transfection efficiency was confirmed by qRT-PCR (Supplementary Fig. 2) and WB assays (Fig. 6A). CCK-8 assays were used to evaluate the effect of SLC27A1 on CRC cell proliferation. Results showed that SLC27A1 knockdown inhibited proliferation of HCT8 and SW480 cells, whereas its overexpression enhanced LoVo and SW620 cell proliferation (Fig. 6B). This was further confirmed by colony formation (Supplementary Fig. 3) and EdU assays (Fig. 6C). Additionally, wound-healing (Supplementary Fig. 4) and Transwell assays (Fig. 6D) were performed to assess the impact of SLC27A1 on CRC cell migration. SLC27A1 knockdown impaired the migratory capacity of HCT8 and SW480 cells, while its overexpression enhanced migration of LoVo and SW620 cells. We further established stable SLC27A1-overexpressing CRC cell lines (SW620-SLC27A1-stable, LoVo-SLC27A1-stable) and their corresponding control stable cell lines (SW620-N1-stable, LoVo-N1-stable). Subsequently, we transiently silenced SLC27A1 expression in these overexpressing cell lines using specific small interfering RNAs (si-SLC27A1). We then evaluated changes in cell proliferation and migration. Our results revealed that the SLC27A1 overexpression-induced enhancement of cell proliferation and migration was significantly reversed upon SLC27A1 silencing (Supplementary Fig. 5). These findings confirmed the oncogenic and pro-migratory functions of SLC27A1 in CRC. To further investigate the oncogenic function of SLC27A1 in vivo, we established a liver metastasis model via intrasplenic injection using SLC27A1-overexpressing LoVo and SW620 cells. Mice injected with SLC27A1-overexpressing cells exhibited a significantly higher burden of liver metastases compared to the control group (Fig. 6E, F), characterized by an increased number and size of visible metastatic nodules on the liver surface. Histopathological analysis via H&E staining further confirmed the presence of metastatic CRC foci within the liver tissues. These in vivo results provide compelling evidence that upregulated SLC27A1 facilitates the metastatic colonization of CRC cells. SLC27A1 overexpression promotes CRC proliferation and metastasis. (A) WB assays validation of SLC27A1 knockdown/overexpression in CRC cells (Original blots are presented in Supplementary Information file). (B) CCK-8 assays showing the regulatory effect of SLC27A1 on CRC cell proliferation. (C) EdU assays confirming the modulatory role of SLC27A1 in CRC cell proliferation. Scale bar: 50 μm. (D) Transwell assays demonstrating that SLC27A1 regulates CRC cell migration. Scale bar: 100 μm. (E) Representative images of liver metastatic lesions in mice models (n = 4 per group). Statistical significance was determined by two‑tailed Student’s t‑test. (F) Representative H&E images of liver tissue in mice models. Scale bar: 50 μm. N, normal, T, tumor. *P < 0.05, **P < 0.01, ***P < 0.001. SLC27A1 promotes epithelial-to-mesenchymal transition (EMT) progression and lactate production in CRC To further explore SLC27A1’s role in CRC, samples were divided into high- and low-expression groups based on its median expression in CRC. We compared the transcriptomes between the two groups, retaining only protein-coding genes, and differentially expressed genes (DEGs) were subjected to GO and KEGG enrichment analyses (Supplementary Fig. 6A-C). Results showed that SLC27A1-associated genes were primarily involved in cellular physiological processes (e.g., cytoskeleton organization, neurodevelopment), signal transduction (e.g., PI3K-AKT signaling pathway), and disease-related pathways (e.g., cancer-related proteoglycan pathways). These included 424 biological processes, 88 cellular components, 24 molecular functions, and 15 KEGG pathways (adjusted p < 0.05 and q < 0.05) (Supplementary Table 1). Bar graphs showed the top 10 biological processes, cellular components, and molecular functions (Supplementary Fig. 6D). Bubble plots and network diagrams further illustrated the top 10 KEGG pathways and their interactions (Supplementary Fig. 6E). Furthermore, we compared transcriptomes between high- and low-SLC27A1 expression groups in CRC patients and performed GSEA on all differentially expressed genes. GSEA revealed that SLC27A1 impacts multiple pathways. Notably, genes involved in EMT, CRC-specific EMT, PI3K-AKT, MAPK, Wnt, cancer-associated pathways, as well as hypoxia were significantly enriched in the high-expression group (Fig. 7A-D and Supplementary Fig. 7A-C). Among these, the EMT pathway exhibited the highest enrichment scores with Normalized Enrichment Score (NES) of 3.641 and 2.558, respectively. Moreover, high SLC27A1 expression was negatively correlated with oxidative phosphorylation, TCA cycle, and pyruvate metabolism pathways (Fig. 7E, F). Based on this, we first explored the association between SLC27A1 levels and EMT in CRC. Then, we assessed the expression of Vimentin, N-cadherin, E-cadherin, and EMT-related transcription factors (Snail, Slug, Twist) in CRC cells following SLC27A1 knockdown or overexpression. Results showed that SLC27A1 knockdown significantly decreased the expression of Vimentin, N-cadherin, Snail, Slug, and Twist, while increasing E-cadherin levels (Fig. 7G, Supplementary Fig. 7D-G). Mechanistically, to identify the specific driver of these phenotypes, we screened multiple EMT-associated pathways via GSEA and found that the PI3K-AKT signaling pathway exhibited the highest NES (Fig. 7C). Consistent with bioinformatic analysis results, our WB assays confirmed that SLC27A1 expression was positively correlated with PI3K-AKT-mTOR pathway activation (Supplementary Fig. 7H). These results indicate that SLC27A1 may influence the biological behavior of CRC cells by activating the EMT pathway through the PI3K-AKT signaling axis. SLC27A1 promotes EMT progression and lactate production in CRC. (A-F) GSEA analysis identified significant associations between high SLC27A1 expression and multiple CRC progression-related pathways, including(A) EMT, (B) EMT in CRC, (C) PI3K-AKT signaling pathway, (D) hypoxia, (E) oxidative phosphorylation, and (F) pyruvate metabolism and TCA cycle. (G) WB analysis of EMT pathway-related protein (N-cadherin, E-cadherin, Vimentin, Snail, Slug, Twist1) levels after SLC27A1 knockdown or overexpression (Original blots are presented in Supplementary Information file). (H) Glucose uptake assay showed that SLC27A1 knockdown inhibited glucose uptake in HCT8 and SW480 cells, while SLC27A1 overexpression promoted it in SW620 and LoVo cells. (I) Lactate production assay indicated that SLC27A1 knockdown reduced lactate production in HCT8 and SW480 cells, whereas SLC27A1 overexpression enhanced it in SW620 and LoVo cells. (J) WB analysis of global protein lactylation level in CRC cells after SLC27A1 knockdown or overexpression (Original blots are presented in Supplementary Information file). *P < 0.05, **P < 0.01, ***P < 0.001. Meanwhile, SLC27A1 encodes a lipid metabolism-related protein, and GSEA indicated its link to glucose metabolism (Fig. 7E, F). Given the close interconnection between lipid and glucose metabolism40–42, we subsequently tested how SLC27A1 expression affects glucose uptake in CRC cells. Results showed it markedly promoted glucose uptake by cancer cells (Fig. 7H). Additionally, given that the TME is generally hypoxic43–45, and the positive correlation between SLC27A1 and hypoxia (Fig. 7D), we hypothesized that SLC27A1 promotes anaerobic glucose metabolism. We then assessed its impact on cellular lactate levels; lactate production assays revealed that SLC27A1 overexpression strongly enhanced lactate production and accumulation (Fig. 7I). Furthermore, we used a pan-lactylation antibody to detect global protein lactylation levels in CRC cells with SLC27A1 overexpression or knockdown (Fig. 7J). We confired that SLC27A1 overexpression markedly upregulated global protein lactylation, whereas SLC27A1 knockdown significantly decreased lactylation levels. Collectively, these findings demonstrate that SLC27A1 promotes EMT progression and activates the PI3K-AKT signaling pathway in CRC. Meanwhile, SLC27A1 enhances anaerobic glucose metabolism, lactate accumulation, and global protein lactylation, thereby exerting oncogenic functions in CRC cells. Correlation between SLC27A1 expression and protein lactylation in CRC Previous experiments demonstrated that high SLC27A1 expression promotes lactate accumulation in CRC46,47. Lactate, one of the major products of glycolytic metabolism, can be converted to lactyl-CoA in cells—a key precursor for lactylation modifications48,49. This suggests SLC27A1 expression may correlate with lactate synthesis and thereby affect protein lactylation. Next, we explored the relationship between SLC27A1 expression and lactylation-related genes in CRC. By screening upregulated DEGs and intersecting them with lactylation-related genes from the GeneCards database, 28 genes related to SLC27A1 expression were identified (Fig. 8A). Figure 8B illustrates the expression correlations between these genes and SLC27A1 in CRC. Further GEPIA2 analysis showed a positive correlation between SLC27A1 and the lactylation gene set in CRC (R = 0.41) (Fig. 8C). Subsequently, we screened genes with a Spearman correlation coefficient > 0.3, namely ULK1, CREBBP, RUNX2, and GCKR. We analyzed their expression correlations with SLC27A1, their expression levels in CRC, and their associations with CRC patient prognosis, respectively. Results showed significant positive correlations in expression levels between SLC27A1 and ULK1, CREBBP, RUNX2, and GCKR (Fig. 8D–G). However, only ULK1 and GCKR exhibited markedly higher expression levels in CRC than in normal colonic epithelial tissues (Fig. 8H). Additionally, survival analysis further revealed that only high ULK1 expression correlated with poor prognosis in CRC patients (Fig. 8I). Thus, ULK1 was selected for subsequent validation. Further verification via WB (Fig. 8J) and qRT-PCR (Supplementary Fig. 8) confirmed the positive correlation between SLC27A1 and ULK1. These results suggest a potential regulatory interplay between SLC27A1 and ULK1. High SLC27A1 levels in CRC may promote protein lactylation in tumor cells, thus affecting patient prognosis. High SLC27A1 expression links to protein lactylation in CRC. (A) Venn diagram showing the intersection between upregulated genes in CRC patients with high SLC27A1 levels and lactylation-related genes from the GeneCards database. (B) Correlation between different lactylation-related genes and SLC27A1 expression. (C) Overall correlation in expression between lactylation-related genes and SLC27A1. (D-G) Expression correlations of SLC27A1 with ULK1, CREBBP, RUNX2, and GCKR. (H) Expression of ULK1, CREBBP, RUNX2, and GCKR in CRC tumor and normal tissues. (I) Prognostic relevance of ULK1, CREBBP, RUNX2, and GCKR in CRC patients. (J) WB assays showing the association between ULK1 protein levels and SLC27A1 expression alterations (Original blots are presented in Supplementary Information file). *P < 0.05, **P < 0.01, ***P < 0.001. Discussion SLC27A1 contributes significantly to tumor initiation and progression, yet only a handful of studies have characterized its role in disease progression. Previous studies reported that in tumors such as ovarian cancer, multiple myeloma, and melanoma, inhibition of SLC27A1 can normalize blood vessels in tumor tissues and enhance the anticancer efficacy of immunotherapy19,22,29,30,50. However, its specific role in CRC remains largely uncharacterized. Herein, we investigated the prognostic value and biological functions of SLC27A1 in CRC, with a focus on its association with immune infiltration and lactylation modification, bridging the existing research gap regarding SLC27A1 in CRC and potentially identifying new candidate biomarkers for CRC diagnosis and treatment. Through bioinformatics analysis of TCGA dataset, SLC27A1 was found to be significantly overexpressed in CRC patients. This result was further validated by more rigorous paired comparison analyses. The expression level of SLC27A1 in CRC tumor tissues was significantly higher than that in adjacent normal tissues. Consistently, in vitro experiments showed that SLC27A1 expression was elevated in CRC cell lines compared with normal colonic epithelial cells. IHC staining of clinical specimens further verified that SLC27A1 was upregulated in CRC tissues. Collectively, these findings support a potential oncogenic role of SLC27A1 in CRC. While similar oncogenic effects have been reported in breast cancer21,25,51, its specific function in CRC requires further investigation. Effective prognostic biomarkers provide critical information for evaluating tumor aggressiveness and predicting clinical outcomes, and thus represent a critical part of personalized and precision medicine29,33. ROC analysis indicated that SLC27A1 can effectively distinguish CRC tissues from normal tissues. TCGA data further revealed that high SLC27A1 expression was associated with advanced TNM stage, clinical stage, and distant metastasis (M1 stage), implying a role in promoting CRC invasion and metastasis. In addition, Kaplan–Meier survival analysis showed that patients with high SLC27A1 expression had shorter overall survival and recurrence-free survival. Multivariate Cox regression confirmed that high SLC27A1 expression served as an independent adverse prognostic factor for CRC patients. These results indicate that SLC27A1 expression has considerable value in predicting prognosis and recurrence risk in patients with CRC. We next explored the biological functions and underlying mechanisms of SLC27A1 in CRC. Functional enrichment analysis of SLC27A1 related genes revealed significant enrichment in EMT, oncogenic signaling pathways, and energy metabolism. Our findings showed that SLC27A1 modulates the expression of EMT-related molecules: it upregulates Vimentin, N-cadherin, Snail, Slug, and Twist, while downregulating E-cadherin. Mechanistically, consistent with GSEA analysis results showing the highest enrichment score for the PI3K AKT pathway, we confirmed that SLC27A1 expression was positively correlated with activation of the PI3K-AKT-mTOR axis. Collectively, these changes drive EMT and promote the proliferation and migration of CRC cells. However, further in vivo validation and functional experiments, including invasion and apoptosis assays, are still needed. Notably, the upstream transcriptional regulation of SLC27A1 in CRC remains unexplored, which is a critical for elucidating the aberrant expression of SLC27A1 in CRC. Lactylation is a novel post-translational modification in which lactate molecules conjugate covalently to lysine residues on proteins, thereby regulating multiple biological processes such as gene expression, cellular metabolism, and signal transduction48,49. Lactate, a major product of glycolysis, can be converted to lactyl-CoA intracellularly. As a critical intermediate in lactylation process, lactyl-CoA synthesis is also closely linked to glucose metabolism48. Glycolysis converts glucose to pyruvate, which is further catalyzed by lactate dehydrogenase (LDH) to lactate. Lactate not only supports energy metabolism but also serves as the primary substrate for protein lactylation47,52–54. Our bioinformatic and experimental results revealed a close association between SLC27A1 and glucose metabolism: SLC27A1 promotes glucose uptake and lactate accumulation in CRC cells. GSEA analysis showed that SLC27A1 negatively correlated with oxidative phosphorylation, pyruvate metabolism, and the citric acid cycle, while positively correlating with hypoxia induction. These findings support the hypothesis that SLC27A1 enhances anaerobic glycolysis, which was further confirmed by lactylation assays. Of note, recent studies have established lactylation as a key post-translational modification that connects metabolic reprogramming to the regulation of EMT. Lactate accumulation has been shown to drive lactylation of core EMT transcription factors, including Snail155 and TWIST156, thereby enhancing their stability and transcriptional activity to promote mesenchymal transition. Although the present study did not directly identify the specific lactylation targets responsible for EMT activation in CRC, these well-established mechanistic links provide a reasonable biological basis for interpreting our observation that SLC27A1-induced lactate production and elevated global lactylation may functionally contribute to EMT progression. In this manner, SLC27A1-mediated metabolic rewiring may converge on lactylation-dependent signaling to modulate the EMT program, thereby facilitating migration and invasion. Future studies will be directed toward identifying the specific lactylated proteins that directly mediate the crosstalk between SLC27A1-driven metabolism and EMT, as well as verifying the causal relationship using site‑specific lactylation markers such as H3K18la and rescue experiments with LDHA inhibition or knockdown. Autophagy and glycolysis are highly conserved biological processes involved in both physiological and pathological cellular conditions. Studies have shown that ULK1-mediated metabolic reprogramming promotes lactylation of the lipid kinase Vps34 by facilitating lactate production. This lactylation enhances autophagic and lysosomal activity, thereby inducing cell autophagy and cancer progression57,58. In line with this regulatory axis, our study confirmed that SLC27A1 significantly promotes lactate accumulation and simultaneously upregulates ULK1 expression. Therefore, drawing upon existing literature, we reasonably hypothesize that the specific functional consequence of this SLC27A1-mediated axis is the enhancement of cytoprotective autophagy, which in turn fuels CRC progression. Although we preliminarily explored the potential regulatory link between SLC27A1 and ULK1, the detailed underlying mechanisms of these functional consequences has been designated as a priority for subsequent research. Notably, although our study delineated the downstream effects of SLC27A1 overexpression, including EMT activation and elevated lactylation, the upstream transcriptional regulators of SLC27A1 in CRC remains largely unexplored. Previous studies demonstrated that SLC27A1 is regulated in a highly tissue specific manner; for instance, by ER-β in breast cancer25, TR4 in adipocytes13, and negatively by PPARα/γ in macrophages59. Given this context-dependent complexity, identifying the specific upstream driver in CRC represents a critical knowledge gap. Therefore, many questions regarding SLC27A1 remain to be addressed in future investigations, particularly the potential regulatory relationship between SLC27A1 expression, its fatty acid metabolism-related functions, and the activation level of the PPAR pathway33,59. Interestingly, with respect to downstream signaling cascades, our study confirmed that SLC27A1 activates the PI3K AKT mTOR pathway in CRC, which differs from its inhibitory effect on AKT signaling in non-cancer disease models (57, 58). This discrepancy suggests a tumor specific oncogenic role of SLC27A1. However, whether SLC27A1 regulates other pivotal signaling cascades, such as the MAPK pathway, to exert additional oncogenic functions remains to be determined. Moreover, given the positive correlation between SLC27A1 and hypoxia revealed by our GSEA analysis, two aspects merit further exploration: the relationship between SLC27A1 and hypoxia-inducible factors, as well as its potential role in angiogenesis-mediated tumor metastasis. Besides, whether SLC27A1 mediates the link between high fat diet and colorectal carcinogenesis is another important direction for future research59–61. The TME is pivotal in mediating cancer progression, with tumor-infiltrating immune cells serving as one of its important components. Particularly, metabolism and immunity are closely interconnected and mutually regulated62,63. As a key lipid metabolism regulator, we hypothesized that SLC27A1 may shape the tumor immune landscape. We therefore analyzed the correlation between SLC27A1 expression and immune infiltration. Our results demonstrated that high SLC27A1 expression was positively correlated with the abundance of NK cells, macrophages, and iDCs, but negatively correlated with Th2 cell infiltration. Macrophages (referred to tumor-associated macrophages, TAMs) are among the most abundant immune cells in the TME. High infiltration of M2-type TAMs in tumor tissues is positively correlated with poor prognosis in various cancers and can induce immune tolerance during tumor initiation and progression64–66. Our results suggest that SLC27A1 may promote macrophage infiltration in the CRC and thereby facilitate tumor immune evasion. DCs are the most potent antigen presenting cells, and their anti-tumor function depends on maturation status67. Here, high SLC27A1 expression increased iDC infiltration levels, implying that SLC27A1 might affect DC maturation and thus influence the prognosis of CRC patients. Traditionally, Th2 cells are thought to promote tumor progression by secreting cytokines like IL 4, IL 5, and IL 10 to suppress anti-tumor immune responses67,68. However, recent studies have found that Th2 cells may exert anti-tumor effects under specific circumstances. In "low-tolerance organs" such as the lungs and brain, the immune response mediated by Th2 cells may encapsulate tumors and restrict their growth through inducing fibrosis, thereby avoiding excessive tissue damage69. Besides, in some tumors (such as small-cell lung cancer and glioblastoma), Th2 cells can kill tumor cells through indirect pathways such as eosinophil activation), and the Th2 response is linked to favorable clinical outcomes70. Our study found that high SLC27A1 expression is related to low Th2 abundance, indicating that high SLC27A1 expression may impair the anti-tumor immune response in CRC. Beyond changes in cell abundance, metabolic reprogramming is increasingly recognized as a key driver of tumor immune evasion. Drawing parallels to FATP2, which has been reported to reprogram neutrophils and MDSCs via fatty acid accumulation to suppress anti-tumor immunity39, we postulate that SLC27A1 may similarly modulate the metabolic plasticity of infiltrating immune cells. By altering the lipid microenvironment, SLC27A1 may establish an immunosuppressive niche. However, the tumor immune microenvironment is highly complex and systematic. Our current results reveal a positive correlation between SLC27A1 and immune cell infiltration as well as immune checkpoint-related molecules, supporting its potential involvement in immune regulation. Further functional investigations, including in vitro co-culture systems and immunocompetent mouse models, will be required to characterize the precise regulatory mechanisms in future work. We acknowledge this as a major limitation of the current study and will further elucidate SLC27A1 mediated immune regulation in future work. Metabolic molecules are tightly linked to immunity71,72. In recent years, immune disorders like psoriasis have been recognized as metabolic diseases, characterized by abnormal levels of metabolites such as glutamic acid73,74. Indeed, our analysis revealed a strong correlation between the lipid metabolism-related molecule SLC27A1 and tumor-infiltrating immune cells. Bridging metabolism, immunity, and disease aids in addressing clinical challenges from multiple perspectives. Critically comparing our findings with existing literature, while SLC27A1 has been primarily characterized as a fatty acid transporter facilitating metastasis in melanoma and breast cancer via lipid metabolic reprogramming, our study contextualizes its role in CRC within a distinct immune-metabolic framework. We propose that SLC27A1 contributes to CRC progression not only through lipid transport but also by fostering an immunosuppressive microenvironment via lactate-mediated metabolic crosstalk. These insights underscore the potential clinical applications of targeting SLC27A1. Given its dual role in promoting oncogenic metabolism and immune evasion, pharmacological inhibition of SLC27A1 could serve as a potential novel therapeutic strategy. Specifically, blocking SLC27A1 might reduce lactate accumulation and reverse the immunosuppressive phenotype, potentially sensitizing “cold” tumors into “hot”. Nevertheless, further investigation into the specific mechanisms is warranted to translate these concepts into clinical practice, including the precise correlation between SLC27A1 and the expression of relevant immune markers, which requires additional analysis and validation. While our findings may offer new insights into the link between SLC27A1 and CRC, this study has several limitations. First, given that our survival and clinical correlation analyses primarily rely on public databases and limited local samples, potential sample bias cannot be ruled out. Consequently, the clinical biomarker potential of SLC27A1 must be interpreted with caution until validated in prospective, large-scale multicenter cohorts. Second, the specific upstream transcriptional regulation driving aberrant SLC27A1 expression in CRC remains a critical knowledge gap that warrants further exploration. Third, although we confirmed that SLC27A1 promotes lactate accumulation and upregulates ULK1, the specific lactylation-modified target proteins downstream of SLC27A1 require more in-depth mechanistic validation. Finally, regarding the TME, unraveling the precise molecular mechanisms of SLC27A1-mediated immune evasion requires specific immunocompetent in vivo models and preclinical therapeutic verification. Addressing these specific experimental gaps, alongside the development of targeted combination therapies, will be the central focus of our future research endeavors. Conclusion In summary, our study systematically reveals the prognostic value of SLC27A1 in CRC, indicating its value as a potential biomarker for predicting treatment outcomes. Mechanistically, we demonstrate that high SLC27A1 expression activates the PI3K-AKT-mTOR signaling axis, thereby driving the EMT process. Furthermore, our in vivo experiments confirm that SLC27A1 significantly promotes CRC metastasis and liver colonization. We also uncover a novel metabolic link where SLC27A1 enhances lactate production and upregulates ULK1, suggesting a potential role in protein lactylation-mediated progression. Collectively, these findings identify SLC27A1 as a critical oncogenic driver and a promising therapeutic target in CRC, laying the groundwork for future investigations into its upstream regulation and lactylation-mediated mechanisms. Materials and methods Data download and analysis Normalized RNA-seq data and corresponding clinicopathological information were retrieved from The Cancer Genome Atlas (TCGA; https://cancergenome.nih.gov/) and Genotype-Tissue Expression (GTEx) databases. These included 647 samples of colon (COAD) and rectal (READ) adenocarcinomas, along with 51 normal tissue samples. Patients with incomplete clinical data were excluded only when specific clinical factors were insufficiently documented. Clinical tissue sample analysis Tumor tissues and matched adjacent normal paraffin-embedded tissue sections were collected from 34 patients with primary CRC. These patients were treated at the Department of Pathology, Xiangya Hospital, Central South University, between 2021 and 2024. All patients underwent radical resection and were pathologically confirmed to have CRC without other malignancies. No patients received preoperative radiotherapy, neoadjuvant chemotherapy, or other special treatments. Written informed consent was obtained from all participants. The study was approved by the Medical Ethics Committee of Xiangya School of Basic Medical Sciences, Central South University (No: 2025-KT029) and conducted in accordance with the Declaration of Helsinki. All procedures adhered to relevant guidelines and regulations. Survival and prognostic analysis Based on the CRC dataset from the TCGA database, ROC analysis was used to evaluate the ability of SLC27A1 mRNA expression levels to distinguish between CRC and normal tissues. Using the TCGA-COADREAD dataset, the correlation between SLC27A1 expression and the prognosis of CRC patients was analyzed via overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). The Kaplan–Meier plotter tool (https://kmplot.com/analysis/) was used to validate these correlations. Construction and validation of a nomogram based on SLC27A1 expression Univariate and multivariate Cox regression analyses were performed to assess whether SLC27A1 acts as an independent prognostic factor in CRC. Included clinical parameters were age, gender, T stage, N stage, M stage, pathological stage, presence of colorectal polyps, and residual tumor. Variables from the multivariate Cox regression were included, and nomograms and calibration plots were generated using the rms and survival packages to predict overall survival at 1, 3, and 5 years. The diagonal line represented the optimal predictor, and discriminative ability was evaluated using the concordance index (C-index). GO and KEGG analyses Tumor samples from the TCGA-COADREAD dataset were divided into low and high SLC27A1 expression groups based on median expression. DEGs were identified using the DESeq2 package in R, with filtering criteria set as |logFC|> 1 and P.adj < 0.05. These genes were subjected to Gene Ontology (GO) enrichment analysis, covering three modules: biological processes (BP), molecular functions (MF), and cellular components (CC). Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was performed using the clusterProfiler package. Correlation analysis between SLC27A1 expression and lactylation in CRC The correlation between SLC27A1 levels and lactylation-related genes (obtained from the Genecards database) was analyzed using R software. The corrlot package was used to visualize pairwise gene correlations. Immune infiltration analysis Based on the TCGA-COADREAD dataset and the GSVA R package, ssGSEA was applied to determine the levels of immune cell infiltration in tumors. Correlations between SLC27A1 expression and immune checkpoint molecules were also analyzed. Results were visualized using the ggplot2 package. Cell culture Human normal colonic epithelial cells (FHC) and CRC cell lines (HCT8, HCT116, RKO, SW480, SW620, HT29, LOVO) used in this study were purchased from the American Type Culture Collection (ATCC). All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. Cells were maintained in a humidified incubator at 37 °C with 5% CO₂. SLC27A1 knockdown and overexpression transfection siRNA targeting SLC27A1 was synthesized by Tsingke Biotechnology. The SLC27A1 overexpression plasmid was constructed in-house, with primer sequences provided in Supplementary Table 2. Cells were seeded in 6-well plates and transfected at approximately 60% confluence using Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific, USA), following the manufacturer’s instructions. The culture medium was replaced after 6–8 h. Cells were harvested 48 h after transfection for subsequent experiments. Quantitative real-time polymerase chain reaction (qRT-PCR) Total cellular RNA was extracted using TRIzol reagent (Vazyme, China). cDNA was synthesized via reverse transcription using the HiScript II Q RT SuperMix for qPCR kit (Vazyme, China). Relative expression levels were calculated using the 2 − ΔΔCt method, with β-actin as the internal reference. Primers for SLC27A1 and other target genes were synthesized by Sangon Biotech (China), and their sequences are listed in Supplementary Table 2. Western blot Cells were lysed on ice with RIPA buffer (Beyotime, China) and protein concentration was quantified using a BCA kit (Dingguo Biotech, China). Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes. After that, membranes were blocked with fat-free milk and incubated overnight at 4 °C with anti-SLC27A1 (Affinity, DF7716, 1:2000) and anti-beta Actin antibody (Proteintech, 20,536–1-AP, 1:10,000). The other specific primary antibodies were as follows: Snail (ABclonal, A11794, 1:1000), Slug(ABclonal, A1057, 1:1000), Vimentin (ABclonal, A19607, 1:40,000), E-Cadherin (ABclonal, A11492, 1:1000), and N-Cadherin (ABclonal, A0433, 1:2000), Twist1 (Affinity, AF4009, 1:2000), ULK1(Abmart, T56902, 1:2000), PI3Kα(Abmart, T40115, 1:2000), AKT1/2/3(Abmart, T55561, 1:2000), Phospho-Akt (Ser473) (Abmart, T40067, 1:2000), mTOR(Abmart, T55306, 1:2000), Phospho-mTOR (S2448) (Abmart, T56571, 1:2000), Pan-Kla(Abmart, P81825, 1:2000), GAPDH(Proteintech, 10,494–1-AP, 1:20,000). After washing, membranes were incubated with the secondary antibody (Proteintech) at room temperature for 1 h. Signals were developed using an ECL kit (Biosharp, China). SLC27A1 expression was analyzed with actin levels as the internal reference. Immunohistochemical (IHC) staining IHC staining was performed on 34 pairs of CRC tissues and adjacent normal tissues. Paraffin sections were deparaffinized, processed for antigen retrieval, and treated with hydrogen peroxide to block endogenous peroxidase. After serum blocking, sections were incubated overnight at 4 °C with anti-SLC27A1 primary antibody (Origene, TA321973S,1:100). They were then incubated with HRP-labeled goat anti-rabbit secondary antibody (1:200 dilution) at 37℃ for 30 min. Staining was developed using a DAB kit (ZSGB-BIO|ORIGENE). IHC scoring criteria are provided in Supplementary table 375. The total score was calculated as the product of positive cell percentage and staining intensity. Samples were categorized into high expression (total score ≥ 6) and low expression (total score < 6) groups based on these values. Cell Counting Kit-8 (CCK-8) Assay Cell proliferation was assessed using a CCK-8 assay kit (Beyotime, China). Cells were seeded into 96-well plates and cultured for 24, 48, and 72–96 h. A mixture of CCK-8 (10 µL) and complete medium (100 µL) was added to each well, followed by incubation at 37 °C for 2 h. Cell absorbance was then measured at 450 nm using a microplate reader. 5-ethynyl-2’-deoxyuridine (EdU) assay Cell proliferation was evaluated using the EdU Cell Proliferation Imaging Kit (RiboBio, China). Cells were plated in 96-well plates at a density of 1 × 104 cells/well. After 24 h, 10 μM EdU was added to the medium and incubated at 37 °C for 2 h. Medium was then removed, fixed cells were incubated with the reaction solution for 30 min in the dark, and then counterstained with DAPI (Beyotime). Representative images were captured via fluorescence microscopy and analyzed with Image J. Transwell assay Migration assays were performed using 24-well plates with Transwell™ chambers (8 μm pore size, Corning). Cells resuspended in serum-free RPMI 1640 were seeded into the upper Transwell chambers (Corning Incorporated, NY, USA) at a density of 2 × 105 cells/well. The lower chambers were filled with 750 μL RPMI 1640 containing 20% FBS. After 24-h incubation, cells were fixed with paraformaldehyde for 30 min and stained with 0.5% crystal violet for 30 min. Migrated cells were captured and analysed using ImageJ software. Colony formation assay Cells were seeded in 6-well plates at 500 cells per well. Following 14-day incubation, cells were fixed in paraformaldehyde for 30 min, stained with 0.5% crystal violet for 30 min. Colonies were captured and analyzed using ImageJ. Wound healing assay Cells were cultured in 6-well plates until confluent. A linear scratch was made across the cell monolayer. Cells were then cultured in serum-free RPMI 1640 for an additional 24, 48, and 72 h. Wound healing was observed microscopically and analyzed with ImageJ. In vivo metastasis assay Male BALB/c nude mice (6 weeks old) were housed and manipulated in strict accordance with the protocols approved by the Institutional Animal Care and Use Committee (IACUC). To establish the liver metastasis model, SLC27A1-overexpressing (or Vector control) CRC cells (LoVo and SW620, 5 × 106 cells resuspended in 50 µL PBS) were injected into the spleen of the mice. After 40 days, the mice were sacrificed (mice were anesthetized by inhalation of 3%–5% isoflurane until the loss of righting reflex. Humane euthanasia was performed via rapid cervical dislocation. All animal experiments were approved by the Institutional Animal Care and Use Committee and carried out in accordance with national animal welfare guidelines and ethical regulations.), and the livers were excised, photographed, and fixed for subsequent histopathological examination (H&E staining) to evaluate the formation of metastatic nodules. Lactate production and glucose uptake assays Lactate production and glucose uptake were measured using a lactate assay kit (BC2235, Solarbio, China) and a glucose uptake kit (WST-8 method; S0554S, Beyotime, China), respectively. Transfected cells were seeded into 6-well plates. After 24-h incubation, medium was removed, and assays were performed according to the manufacturers’ instructions. Absorbance was detected using a microplate reader at 570 nm for lactate and 450 nm for glucose uptake. Lactate concentrations were determined against a standard curve. Bioinformatics analysis We have supplemented complete and detailed information on all R packages and their exact versions used in this study, as follows: single sample gene set enrichment analysis (ssGSEA) was performed using the GSVA package (version 1.48.0); univariate and multivariate Cox regression analyses for prognostic evaluation were conducted using the survival package (version 3.5–8); the prognostic nomogram was constructed and validated using the rms package (version 6.7–1); additional analyses including differential expression screening and correlation analysis relied on the limma (version 3.56.2) and ggplot2 (version 3.4.4) packages. Statistical analysis SLC27A1 expression levels were visualized using box plots and scatter plots. The median expression was used as the cutoff for grouping to ensure balanced sample distribution, reduce the influence of outliers, and avoid subjective selection bias. Spearman correlation analysis was performed to evaluate the correlation between SLC27A1 and its related genes. Potential prognostic factors were identified using univariate and multivariate Cox analyses. Student’s t-test was applied to analyze statistical differences between two groups. In all analyses, *, **, and *** indicate P < 0.05, P < 0.01, and P < 0.001, respectively. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Acknowledgements Not applicable. Abbreviations Colorectal cancer Solute carrier family 27 member 1 Fatty acid transport protein 1 Fatty acid transport protein 2 Fatty acid-binding protein 1 Fatty acid-binding protein 5 Microsatellite instability The Cancer Genome Atlas Colon adenocarcinomas, Rectal adenocarcinomas Overall survival Disease-specific survival Progression-free interval Gene Ontology Biological processes Molecular functions Cellular components Kyoto Encyclopedia of Genes and Genomes Gene set enrichment analysis Quantitative real-time polymerase chain reaction Immunohistochemical The tumor microenvironment Differentially expressed genes Epithelial-to-mesenchymal transition Author contributions KW conceived of and designed the whole structure of the manuscript. The primary manuscript was written by YQ and SD after reviewing the literature. YQ drafted and SD revised table. SD designed and generated the figure, and YQ helped modified the final figure. Final manuscript revision was done by KW and JZ. All authors read and approved the submitted version. Funding This work was supported by the National Natural Science Foundation of China (No. 81972490) and the Hunan Provincial Natural Science Foundation of China (No.2024JJ8190). Data availability The public RNA-seq data and corresponding clinical information of TCGA-COAD and TCGA-READ were retrieved from the UCSC Xena browser (https://xena.ucsc.edu/). All analyzed datasets are publicly available at https://xenabrowser.net/datapages/. All data supporting the conclusions of this study are provided in the main text and supplementary materials. Additional data can be obtained from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Ethical approval This study was reviewed and approved by The IRB of School of Basic Medical Science, Centrạl South University. The design and methods of this research comply with relevant regulations, and the ethical approval number is 2025-KT029. The Institutional Animal Care and Use Committee of Central South University approved the protocols for animal care and euthanasia. All animals used in the experiments were performed according to the approved protocols (approval number: XMSB-2026–0253). Consent for publication Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yu Qi and Shumin Deng contributed equally to this work and share the first authorship. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Data Availability Statement The public RNA-seq data and corresponding clinical information of TCGA-COAD and TCGA-READ were retrieved from the UCSC Xena browser (https://xena.ucsc.edu/). All analyzed datasets are publicly available at https://xenabrowser.net/datapages/. All data supporting the conclusions of this study are provided in the main text and supplementary materials. Additional data can be obtained from the corresponding author upon reasonable request.